



## General Assembly Minutes from 3 June 2024

*In attendance:*

### Session 1 (2:00 am CT/ 9:00 am CET):

A-Gaelle Bellozzi	Alastair Stewart	Amrita Ahluwalia
Baiba Jansone	Beáta Sperlagh	Bikash Medhi
Bridin Murnion	Carl Kirkpatrick	Clare Guilding
Dagmar Stoiber	Darko Modun	Dubravka Svob Strac
Emilio Clementi	Eriika Savontaus	Francesca Levi-Schaffer
Gordana Dragovic	Ingolf Cascorbi	Kevin Pflieger
Makhotso Lekhooa	Mamza Mothibe	Michael Spedding
Octavia Sabin	Olayinka Ogunleye	Pierre Marquet
Rachel Lambert-Forsyth	Sasa Vasilev	Stephan Kellenberger
Steve Alexander	Vanessa Steenkamp	Vladimirs Pilipenko
Jesse Howard (PMG)	Kim Gibson-Pierce (PMG)	

### Session 2 (10:00 am ET/ 4:00 pm CET):

Antonio Rodriguez Artalejo	Caroline Samer	Clare Guilding
Claudio Coddou	Dave Jackson	Emilio Clementi
Flávio Reis	Francesca Levi-Schaffer	Guillermo Antonio Diaz Araya
Ingolf Cascorbi	Maria José Diógenes	Michael Jarvis
Michael Spedding	Olayinka Ogunleye	Patricio Iturriaga
Pierre Marquet	Steve Alexander	Susana Gorzalczany
Vanessa Minervini	Xinxin Ding	
Jesse Howard (PMG)	Kim Gibson-Pierce (PMG)	

***This combined attendance represents ~20,400 society votes.***

***The voting scheme is described in Appendix A.***

## Minutes:

### 1. President's Welcome and Address:

- a. Dr. Ingolf Cascorbi, current president, welcomed everyone in attendance to the General Assembly meeting and explained that as an international society, two meetings would be held to reach the society's global audience (one at 9 CET and the other at 16 CET)
  - i. As part of the IUPHAR statutes, it was necessary to hold a meeting every two years after the elections to keep the member societies informed of the activities of IUPHAR and the executive committee.
  - ii. This meeting also serves as an opportunity to introduce the incoming President (Dr. Francesca Levi-Schaffer) and incoming Secretary General (Dr. Emilio Clementi) and for them to offer future propositions.
  - iii. Showed the current global representation map of IUPHAR which indicated a membership of 59 Member Societies, Representing ~37,000 society members.
- b. Introduced the IUPHAR Executive Committee along with the IUPHAR Executive Committee structure.
  - i. Executive Committee from July 2022
    1. Prof. Ingolf Cascorbi, President
    2. Prof. Francesca Levi-Schaffer, President-Elect
    3. Prof. Michael Spedding, Secretary General
    4. Prof. Amrita Ahluwalia, Basic and Translational Pharmacology Section Chair
    5. Prof. Caroline Samer, Clinical and Translational Pharmacology Section Chair
    6. Prof. Stephen Alexander, NC-IUPHAR Committee Chair
    7. Dr. Vanessa Minervini, Early Career Researchers Section Chair
    8. Dr. Clare Guilding, Education Section Chair
    9. Prof. Beáta Sperlagh, Governance Section Chair
    10. Prof. Emilio Clementi, Member-At-Large (2 years)
    11. Dr. Olayinka Ogunleye, Member-At-Large (4 year)
    12. Jesse Howard, Director Association Strategy
    13. Addison Propes, Member Service Manager
    14. Prof. Guan-Hua Du, Coopeted Member
    15. Prof. Guilherme Suarez Kurtz, Coopeted Member

16. Prof. Bikash Medhi, Cooped Member
- ii. Reviewed Governance structure including election timelines per position:
  1. President: Elected 2024-2026
  2. President-Elect: to be elected until 2026
  3. Secretary General: to be elected until 2028.
  4. Treasurer: Elected 2022-2026
  5. Chair- Clinical and Translational Pharmacology Section: elected 2022-2026.
  6. Chair-Basic and Translational Pharmacology Section: to be elected until 2028.
  7. Chair- NC-IUPHAR: Elected 2022-2026
  8. Chair- Education Section: to be elected until 2028.
  9. Chair- Governance Section: to be elected until 2028.
  10. Chair- Early Career Committee: Elected 2022-2026
  11. EC Member-at-Large: to be elected until 2028.
  12. EC Member-at-Large: elected 2022-2026.
- c. Dr. Cascorbi also presented the election results for the 2024-26 term:
  - i. President-elect: Prof. Caroline Samer, Switzerland.
  - ii. Secretary General: Prof. Emilio Clementi, Italy
  - iii. Chair Basic and Translational Pharmacology Section: Dr. Bikash Medhi
  - iv. Chair Education Section: Prof. Clare Guilding, United Kingdom
  - v. Chair Governance Section: Prof. Beáta Sperlagh, Hungary
  - vi. Member-at-Large: Prof. Gang Hu, China

**2. Vote held to confirm election results:**

- i. **Session 1: 19 votes in favor, no abstentions, no votes against**
- ii. **Session 2: 25 votes in favor, no abstentions, no votes against**
- iii. **Thus, the motion was carried unanimously.**

3. Dr. Cascorbi introduced the incoming IUPHAR executive committee:
  - a. Prof. Levi-Schaffer, President
  - b. Prof. Caroline Samer, President-Elect
  - c. Prof. Emilio Clementi, Secretary General.
  - d. Prof. Pierre Marquet, Treasurer
  - e. Prof. Bikash Medhi, Chair, Basic and Translational Pharmacology Section
  - f. (Currently Vacant) Chair, Clinical and Translational Pharmacology Section
  - g. Prof. Stephen Alexander, Chair, NC-IUPHAR Committee

- h. Dr. Vanessa Minervini, Chair, Early Career Researchers
- i. Dr. Clare Guilding, Education Section
- j. Prof. Beáta Sperlagh, Governance Section Chair and meetings secretary
- k. Prof. Olayinka Ogunleye, Member-at-Large
- l. Prof. Gang Hu, Member-at-Large
- m. Jesse Howard, Director, Association Strategy
- n. Kimberly Gibson, Administration Officer
  - i. Coopted members to be determined by the new EC.
- o. Spoke also on the new governance structure and the improvements in communication between the committees and the executive board.
  - i. Sections are now organized:
    - 1. Clinical and Translational Pharmacology Section which is made up of the following committees:
      - a. Geriatric Pharmacology
      - b. Pediatric Pharmacology
      - c. Pharmacovigilance and Pharmacoepidemiology
      - d. Global Health Pharmacology and Therapeutics
      - e. Pharmacogenetics, Drug Metabolism and Transport
    - 2. Basic and Translational Pharmacology, which is made up of the following committees:
      - a. Gastrointestinal Pharmacology
      - b. Immuno-pharmacology
      - c. Pharmacology of Natural Products
      - d. Neuropharmacology and Psychopharmacology
      - e. Cardiovascular Pharmacology
      - f. Reproducibility and Transparency Committee
    - 3. NC-IUPHAR
      - a. NC-IUPHAR Subcommittees
      - b. Database
    - 4. Education Section
      - a. Pharmacology Education Project (PEP)
    - 5. Early Career Section
      - a. Early Career Committee
    - 6. Governance Section
      - a. Nominations Committee
  - ii. It is noted that all sections report to the Executive Committee and that the new governance structure has worked well.

4. Dr. Michael Spedding, current secretary general, spoke on IUPHAR's achievements since the last world congress in 2023 in Glasgow. He congratulated the British Pharmacological Society on the great success of WCP2023 in Glasgow and hoped that all societies would be represented at WCP 2026 in Melbourne. There is an opportunity to bid for WCP 2030 now open. Other achievements include:
  - a. Utilizing Parthenon as an excellent resource, but changes of personnel (Kimberly Gibson has now replaced Addison Propes)
  - b. GuidetoMalariaPharmacology.org completed (via Gates-funded Medicines for Malaria Venture).
  - c. Thirty-five IUPHAR Pubmed references since Glasgow
  - d. Regional meetings in South America (Spanish and Portuguese-speaking countries) Eight presentations in webinars in India,  
Six webinars in natural products with ECRs organized by CNPHARS/IUPHAR, Major CNPHARS/IUPHAR NP meeting programmed in July  
SIF/IUPHAR evidence-based NP database now ~360 compounds linked mechanism.
  - e. IUPHAR meetings secretary appointed (Beata Sperlagh)
  - f. Increased social media interaction and visibility.
  - g. IUPHAR News- please circulate to local members.
  
5. Dr. Amrita Ahluwalia (Michael Spedding in Session 2) reported on the Basic and Translational Pharmacology Section.
  - a. New section was created 2 years ago.
    - i. In the first year, the section named 8 committees to participate with the main goal of eventually covering all the main areas of pharmacology.
      1. Members include the chairs of Immunopharmacology, Natural Products, GI Pharmacology, Neuro/Psychopharmacology, Cancer Pharmacology, Cardiovascular Pharmacology, Environmental Pharmacology, and the chair of the Reproducibility and Transparency Committee
    - ii. Covered the section's achievements since WCP23 Glasgow which include:
      1. A new Cancer Pharmacology Chair has been appointed- Prof. Jian Ding of Shanghai Institute of Materia Medica.
        - a. The Cancer committee is currently being formed and members invited.

2. The Neuropsychopharmacology Committee Chair had to step down due to ill health, and the new leadership of the committee is Prof. Gary Stephens (BPS).
  3. The GI Pharmacology Committee elected a new Chair Thomas Brzozowski (Hungarian Pharmacology Society)
  4. The IUPHAR Basic and Translational Section created a new website format being implemented.
  5. The committee established regional representation across each committee to be more inclusive.
  6. Hosted 3 webinars.
    - a. 2x NP (ERC Focused)
    - b. 1x immunopharmacology.
    - c. Further 3 in progress.
  7. Two articles published across the committees.
  8. Committees organized accepted symposia at regional Pharmacology meetings.
    - a. BPS- Dec 2024, ASCEPT 2024
  9. Immunopharmacology established links with Africa:
    - a. *Africa-Europe Cluster of Research Excellent (CoRE) in Non-Communicable Diseases and Multimorbidity.*
6. Dr. Michael Spedding (Session 1) and Dr. Caroline Samer (Session 2) reported on the Clinical and Translational Section
- a. The Clinical and Translational section is made up of 6 committees,
    - i. A Clinical Pharmacology Committee has been created.
  - b. World Smart Medication Day, an annual event in May to promote the visibility of the clinical pharmacology world: 3<sup>rd</sup> successful edition in 2024 on Drug Evaluations at the extremes of ages.
  - c. Renewal of WHO/IUPHAR collaboration plan (2025-2027) ongoing, continued contribution to WHO 3<sup>rd</sup> Global safety challenge (“Medication without harm”) and technical input to WHO documents.
  - d. Education: Numerous symposia/courses, including Latin-American countries course, sponsoring EACPT 2024 Rotterdam, co-sponsoring of WHO medication without harm meeting in Colombo (July 2024) by the Sri Lanka Association of Clinical Pharmacology and Therapeutics, etc.
  - e. Several publications and position papers
  - f. BJCP Themed Issue based on WCP symposia from the Geriatric, Global Health & Pharmacogenetics committees.

- g. Strategies from IUPHAR Geriatric Committee: addressing the gaps in evaluation of new drugs for older adults. Journal of the American Geriatric Society.
  - h. Partnership with the Council for International Organizations of Medical Sciences (CIOMS)
  - i. Aim to increase collaborations with other sections and subsections, particularly with ECRs.
7. Dr. Steven Alexander (Session 1 and 2) updated the General Assembly on the achievements of the Nomenclature and Standards Committee (NC-IUPHAR) as well as the publishing impact of the database at [guidetopharmacology.org](http://guidetopharmacology.org).
- i. Also discussed was the internal organization of NC-IUPHAR which includes >500 scientists and makes up ~105 subcommittees, arranged primarily by molecular targets (Attachment, slide 16)
8. Dr. Clare Guilding (Session 1 and 2) reported on the Education Section
- a. Now made up of 20 new councilors.
  - b. They created new subcommittees, one focusing on communication, which produced two newsletters detailing the section's happenings.
  - c. Other subcommittees include website updates and two major meetings co-organized with Melbourne Institute of Pharmaceutical Sciences (MIPS)
    - 1. with a further in-person gathering planned for this summer in Italy for a focus on core concepts.
9. Dr. Michael Spedding reported on IUPHAR's New Member Societies
- a. Armenian Pharmacologist Scientific Public Organization
  - b. Indonesian Pharmacology Society
  - c. The Romanian Society of Pharmacology
  - d. The Sri Lanka Association of Clinical Pharmacology and Therapeutics.
    - i. Also helped other small, nascent societies in Tunisia, and Nigeria, and looking to see how we can help a society in Panama.
    - ii. IUPHAR has been able to supply first-class speakers for >20 virtual pharmacology society meetings around the world.
- 10. Vote for Approval of the actions of the Executive Committee for the period 2022-2024**
- a. **Session 1: 21 votes for, no abstentions or votes against**
  - b. **Session 2: 26 votes for, no abstentions or votes against**

**c. Thus, the actions of the Executive Committee and the officers for the period from the last general meeting were approved.**

11. Dr. Pierre Marquet provided the Treasurer's Report for 2022-23, detailing income, expenses, and actual/projected balances.

a. Income

i. 2022: \$205,748

ii. 2023: \$178,139

1. *net difference of -\$27,609 (far less than planned, in part due to the absence of revenue from WCP2023 in Glasgow).*

b. Expenses:

i. 2023: \$202,487

ii. *\$48,000 more than 2022, but ~\$30,000 less than budgeted.*

c. Balance 2023:

i. Operational balance:  $178,139.28 - 202,486.92 = -\$24,347.64$

ii. Virtual balance:  $178,139.28 + 45,632.76 - 202,486.92 = +\$21,285.12$

iii. The provisional budget for 2024 plans for \$197,500 of income and \$209,700 of expenses, operating at a tentative (small) net loss.

**12. Vote for the Approval of the actions of the treasurer for the period 2022-2024**

i. **Session 1: 20 votes for, no abstentions or votes against**

ii. **Session 2: 37 for, no abstentions or votes against**

iii. ***Thus, the actions of the treasurer and the financial statements of IUPHAR were approved for the period from the last general meeting.***

13. Dr. Francesca Levi- Schaffer thanked Dr. Michael Spedding, Dr. Ingolf Cascorbi, and Dr. Amrita Ahluwalia (outgoing officers) for their time in office and offered time for their outgoing statements:

a. Dr. Ahluwalia thanked the committee members for their willingness to participate and from around the globe. She assured the General Assembly that the Basic and Translational Committee would be in good hands under her successor and with the support of the pharmacological society.

b. Dr. Ingolf Cascorbi thanked the General Assembly for his 6 years as President of IUPHAR. He said his time in this role had been fantastic and he enjoyed working with those serving on the board, in particular thanking the executive board's productivity and the guidance of the outgoing Secretary General. Dr.



Cascorbi also emphasized the importance of a global scientific society now more than ever, with science serving to unify people worldwide.

- c. Dr. Michael Spedding pointed out that he has been working with IUPHAR (either as a NC-IUPHAR secretary or chair (1990-2015) to secretary general (2014-present) for 34 years. It has been a privilege to structure modern molecular pharmacology with NC-IUPHAR and to coordinate pharmacology globally with IUPHAR, even if this gigantic task can never be fully achieved! During his tenure, he has found great pleasure in some of the matters that initially worried him on taking in the role of secretary general: helping pharmacology in China, India and Africa and making an impact in resource-limited countries. He has had great pleasure working with the president and EC and is looking forward to helping IUPHAR in the future regarding two new initiatives:
  - i. Environmental pharmacology
    - 1. Four hundred million tons of pesticides are applied to the planet, and most of these have modes of action defined by Croplife, the main consortium of producers.
    - 2. Yet a main measure of activity is toxicological, LD50s, even though we know what concentrations may be in soil or groundwater. Thus we propose that environmental pharmacology, with Kis at site of action and pharmacology at pest, and bystander species will give a better measure of risks to the environment.
      - a. Steve Alexander and Michael Spedding
  - ii. Industry/biotech contact.
    - 1. The pharmaceutical industry is the source of most drugs, and has, in the past, supported IUPHAR in classifying receptors and sites for drug action, but this has been less evident over the last two decades.
      - a. Scientific Liaison : Michael Spedding

#### 14. Future Propositions:

- a. Welcome and greeting from Dr. Francesca Levi-Schaffer:
  - i. Dr. Levi-Schaffer is the incoming President for IUPHAR during the 2024-2026 term, and as such addressed her aims as the new President:
    - 1. To further scientific research, development, and knowledge of pharmacology

2. To harmonize pharmacology where the ideas, perceptions and priorities vary due to location, culture, education, and gender.
3. To advance education in pharmacology

ii. Dedication to IUPHAR's Strategic Plan:

1. Vision: To be the leading organization in the world that represents, promotes, and advances pharmacology and its contributions to the global biomedical and healthcare sciences.
2. Mission: IUPHAR, in collaboration with pharmacology societies from around the world, will support pharmacology research, education, and their application to improve global health.
3. Core Values:
  - a. Collaboration: Facilitation the exchange of information and discussion among investigators and practitioners of pharmacology, focusing on both the acquisition of new knowledge and its applications to clinical care using evidence-based approaches.
  - b. Innovation: Promoting the science, development, and clinical application of pharmacology.
  - c. Integrity: Fostering the ethical conduct and integrity of research, practice, and dissemination of the best practices in pharmacology.
  - d. Generativity: Developing early career investigators and basic and clinical scientists interested in pharmacology and extending the reach of the field.
  - e. Inclusivity: Promoting and welcoming equality, diversity, and inclusion within the society and the field.
  - f. Accessibility: Ensure accessibility in resource-limited countries.

iii. Specific Actions and Activities to Achieve the Aims

1. To increase communication and cooperation with other international science organizations (i.e., WHO, ISC, IUIS etc.) and more importantly with national and regional societies
2. To open channels of communication where locales, education, culture, and gender have different perspectives and priorities in pharmacology. To make pharmacology inclusive on a global

level with access open to all, regardless of geographical location

3. To support education of pharmacology focusing on the frame of the Pharmacology Education Project (PEP), and to foster R&D of pharmacology globally and especially in low-income countries.
4. To establish new IUPHAR committees, i.e., on respiratory, GU, cancer, etc., and to promote new projects in areas such as environmental pharmacology.
5. To organize future IUPHAR world congresses, general assemblies (every year on a virtual platform), webinars, and meetings.

b. WCP2026 Melbourne, Australia

- i. The 20<sup>th</sup> World Congress of Basic and Clinical Pharmacology sponsored by ASCEPT And IUPHAR, will be held in Melbourne, Australia 12-17 July 2026.
- ii. IUPHAR trusts that we will have a large participation from the pharmacology community worldwide for this important meeting.

c. Welcome and greeting from incoming Secretary General, Dr. Emilio Clementi:

- i. Introduced himself with what he is currently doing as a Member-at-Large and will continue as Secretary General:
  1. Pharmacological Research is an IUPHAR-affiliated journal since 2020.
  2. Taking this as an opportunity to:
    - a. Enhance the visibility of affiliated Societies through Special Issues highlighting their history, their main areas of scientific activity, and their future with a section on “the promise”- i.e. articles by young investigators
    - b. Promote interactions and bonding among brilliant IUPHAR young scientists through collaborative review articles on hot topics (in collaboration with Dr. Vanessa Minervini and the Early Career Committee)
    - c. Worked to implement new strategies for current activities/partnerships/commitments.
- ii. IUPHAR- Strengths and Weaknesses from his point of view

1. The Union has now a good structure with clearly defined “duties” for the Chairs of the various sections and committees – people start working together on defined projects.
2. Lean structure with no real headquarters and administration (though Parthenon is doing a good job)
3. Interactions with IUPHAR- affiliated national and regional societies
4. NC-IUPHAR: a strength and an (economic) weakness

iii. Future Steps

1. To interact with affiliated societies on a more direct (one to one meeting) and regular basis to:
2. Listen to their perception of IUPHAR and get suggestions on how to improve IUPHAR strategic actions.
3. Plan strategic activities that may improve affiliated societies’ standing and visibility.
4. Involve as much as possible members from affiliated societies into the IUPHAR activities.
5. To define priority plans for IUPHAR to develop – e.g. Education program.
6. To address the financial issues around NC-IUPHAR
7. To help the Meetings-Secretary position to coordinate IUPHAR and affiliated societies webinars.
8. Increased ECR involvement in IUPHAR (committees - education program, website)
9. Interaction with Industry
10. Environmental Pharmacology

d. Call for bids for WCP30.

- i. Any member of society interested in hosting the upcoming World Congress for 2030 can find more information about the bidding process on our website (IUPHAR.org) or by emailing the Executive Office at admin@IUPHAR.org.

15. Discussion

- a. Discussion from Sessions 1 and 2:
  - i. For small societies from resource-limited countries to have a low or reduced membership fee.

16. Thank you from the current President, Dr. Ingolf Cascorbi, and close of the session.

- a. Total meeting time: 1 hour, +/- 5 minutes (both sessions).

## Appendix A

The voting scheme is described in the IUPHAR Operating Manual (found online at IUPHAR.org) and is described as such on pages 9-10:

“IUPHAR no longer uses the delegate system. Instead of delegates, each Full Member will be given a number of votes, in proportion to the size of the Full Member. The table below shows how the number of votes is calculated.”

<b>Number of Members</b>	<b>Number of Votes</b>
Below or equal to 200	1
201 members to 400 members	2
401 members to 600 members	3
601 members to 800 members	4
801 members to 1000 members	5
1001 members to 1200 members	6
1201 members to 1400 members	7
1401 members to 1600 members	8
1601 members to 1800 members	9
1801 or more members	10

These votes are calculated based on the number of members as reported by the individual member society. As an example, the American Society for Pharmacology and Experimental Therapeutics (ASPET) has reported 4,873 members. Based on the vote calculation scheme above, their voting delegate would receive the equivalent of 10 votes per business item. This serves to weigh their vote to represent their representative body more adequately.

Session 1	Society	Election	Board	Treasurer
Carl Kirkpatrick	ASCEPT	2	2	2
Kevin Pflieger	ASCEPT		0	
alastair stewart	Asia Pacific Federation of Pharmacologists			
Dagmar Stoiber	Austrian Pharmacological Society			
Amrita Ahluwalia	BPS	10	10	10
Clare Guilding	BPS	0	0	0
Rachel Lambert-Forsyth (BPS)	BPS			1
Steve Alexander	BPS	0	0	0
Darko Modun	Croatian Pharmacological Society	1	1	1
Dubravka Svob Strac (Croatia)	Croatian Pharmacological Society	0	0	0
Pierre Marquet	French	2	2	2
Eriika Savontaus	Finnish Pharmacological Society		3	3
Ingolf Cascorbi	German Society for Experimental and Clinical Pharmacology and Toxicology			
Beata Sperlagh	Hungarian Society for Experimental and Clinical Pharmacology	2		
Bikash Medhi	Indian Pharmacological Society			
Francesca Levi-Schaffer	Israel Society for Physiology and Pharmacology			
Emilio Clementi	Italian Pharmacological Society			
Baiba Jansone	Latvian Society of Pharmacology			
Vladimirs Pilipenko	Latvian Society of Pharmacology			
Gordana Dragovic	Serbian Pharmacological Society	1	1	1
Sasa Vasilev (Serbia)	Serbian Pharmacological Society			
Makhotso Lekhooa	South African Society for Basic and Clinical Pharmacology	1		
Mamza Mothibe	South African Society for Basic and Clinical Pharmacology			
Stephan Kellenberger	Swiss Society of Pharmacology and Toxicology		1	
Octavia Sabin	The Romanian Society of Pharmacology		1	
A-Gaelle Bellozzi				
Bridin Murnion				
IUPHAR Executive Office				
Kimberly's Iphone				
Michael Spedding				
Olayinka Ogunleye				
Vanessa Steenkamp				
Session 1 Totals		19	21	20

## Appendix C

Vote calculation based on representative votes

Session 2	Society	Election	Board	Treasurer
Susana Gorzalczany	Argentine Society for Experimental Pharmacology	1		1
Dave Jackson	ASPET			
Vanessa Minervini	ASPET		10	10
Xinxin Ding	ASPET	0		0
Michael Jarvis	ASPET			
Clare Guilding	BPS	10	10	10
Steve Alexander	BPS			
Claudio Coddou	Chilean Society of Pharmacology			1
Guillermo Antonio Diaz Araya	Chilean Society of Pharmacology		1	0
Patricio Iturriaga	Chilean Society of Pharmacology			0
Caroline Samer	European Society for Developmental, Perinatal and Pediatric Pharmacology		1	
Pierre Marquet	French Society	2	2	2
Ingolf Cascorbi	German Society for Experimental and Clinical Pharmacology and Toxicology	10		10
Francesca Levi-Schaffer	Israel Society for Physiology and Pharmacology	1		1
Emilio Clementi	Italian Pharmacological Society		9	9
Michael Spedding	IUPHAR	0		0
Flávio Reis	Portuguese Society of Pharmacology	1	1	
Maria José Diógenes	Portuguese Society of Pharmacology		0	1
Antonio Rodríguez Artalejo	Spanish Society of Pharmacology			
IUPHAR Executive Office				
Olayinka Ogunleye				
Session Totals		25	34	45
		Election	Board	Treasurer
	Session 1 Totals	19	21	20
	Session 2 Totals	25	34	45
	Aggregate Session Totals	44	55	65
	Total Members	20,407		

IUPHAR Virtual General Assembly - Session 1	IUPHAR Virtual General Assembly - Session 2
Mon 6/3/2024 3:00 AM - 4:00 AM	Mon 6/3/2024 10:00 AM - 11:00 AM
<a href="https://us02web.zoom.us/j/87574013981">https://us02web.zoom.us/j/87574013981</a>	<a href="https://us02web.zoom.us/j/88584927468">https://us02web.zoom.us/j/88584927468</a>

anaida@pharm.am;  
 carl.kirkpatrick@monash.edu;  
 kevin.pfleger@perkins.uwa.edu.au;  
 ross.vlahos@rmit.edu.au  
 declined;ascept@ascept.org;  
 bridin.murnion@health.nsw.gov.au;  
 akos.heinemann@medunigraz.at;  
 dagmar.stoiber@kl.ac.at;  
 michael.m.pohl@astrazeneca.com;  
 guido.demeyer@uantwerpen.be;  
 v.seutin@ulg.ac.be;  
 wim.martinet@uantwerpen.be;  
 zhaoying@imm.ac.cn;  
 zhangyx@bmi.ac.cn;  
 dsvoib@irb.hr;  
 jaska.mrsic.pelcic@uniri.hr;  
 milan.grundmann@osu.cz;  
 urbanek@fnol.cz;  
 ebj@ph.au.dk  
 declined;gunnar.toft@ph.au.dk;  
 mwielsoe@ph.au.dk;  
 alar.irs@ravimiamet.ee;  
 anti.kalda@ut.ee;  
 puheenjohtaja@sfi.fi;  
 rahastonhoitaja@sfi.fi;  
 sihteeri@sfi.fi;  
 erisan@utu.fi;  
 dominique.deplanque@chru-lille.fr;  
 flibert@chu-clermontferrand.fr;  
 nicolas.picard@unilim.fr  
 declined;julia.stingl@uni-ulm.de;  
 apapapet@pharm.uoa.gr;  
 jksko@hkbu.edu.hk;  
 jar@cuhk.edu.hk.notinuse;  
 noreply8@noreply.com;  
 noreply9@noreply.com;  
 furzsu@pharma.sote.hu;  
 ferdinandy.peter@med.semmelweis-univ.hu;  
 bhagirath70@gmail.com;  
 drshiv@synchronresearch.com;  
 drbikashus@yahoo.com;  
 msjorjani@sbmu.ac.ir;  
 dascaln@tauex.tau.ac.il;  
 yhaitin@tauex.tau.ac.il;  
 moshegil@post.tau.ac.il;  
 sif.farmacologia@sigr.it;  
 mmishina@fc.ritsumei.ac.jp;  
 aakaike@pharm.kyoto-u.ac.jp;  
 yanai@mail.tains.tohoku.ac.jp;  
 flute@med.hokudai.ac.jp;  
 ykanai@pharma1.med.osaka-u.ac.jp;  
 anguantai@yahoo.com;  
 okalebof@yahoo.com;  
 baiba.jansone@lu.lv;  
 vladimirs.pilipenko@lu.lv;  
 ksenija\_lucija.bahire@lu.lv;  
 nafeeza@salam.uitm.edu.my;  
 dr\_azlini@iiium.edu.my;  
 dharmani79@um.edu.my;  
 anthony.fenech@um.edu.mt;  
 roger.ellul-micallef@um.edu.mt;  
 drkhinchit@gmail.com;  
 khinarmyint67@gmail.com;  
 drmyatmyatsoe2010@gmail.com;

amgenaro@yahoo.com.ar;  
 paula.schajkuevich@gmail.com;  
 sgorza16@gmail.com;  
 danielaaq@gmail.com;  
 marco.martins@ioc.fiocruz.br;  
 teresadc@farmacia.ufrgs.br;  
 bcarleton@popi.ubc.ca;  
 donald.miller@umanitoba.ca;  
 ramon.sotomayor@uv.cl;  
 gadiaz@ciq.uchile.cl;  
 patricio.iturriaga@ufrontera.cl;  
 ccoddou@ucn.cl;  
 direccion@asocolfarma.com;  
 tesoreria@asocolfarm.com;  
 acelia@cencec.sld.cu;  
 mariamarrero9131@gmail.com;  
 c.waeber@ucc.ie;  
 diogenes@medicina.ulisboa.pt;  
 freis@fmed.uc.pt;  
 svaz@medicina.ulisboa.pt;  
 tesorero@se-fc.org;  
 ag@icf.uab.cat;  
 secretary@se-fc.org;  
 valentin.cena@gmail.com;  
 pepo.brea@usc.es;  
 sharon@ascpt.org  
 declined;issam.zineh@fda.hhs.gov;  
 cbeckphd@yahoo.com;  
 john.schuetz@stjude.org;  
 jarvismf@comcast.net;  
 djackson@aspnet.org;  
 xding@pharmacy.arizona.edu;  
 daws@uthscsa.edu;  
 neumaier@uw.edu;  
 ncanasta@utmb.edu;  
 kcorrell@aim-hq.com;  
 todd.a.wisniewski@pfizer.com;  
 lecountclark@gmail.com;  
[jiz175@ucsd.edu](mailto:jiz175@ucsd.edu)




drminwun@gmail.com;  
eieimondecember@gmail.com;  
rick.greupink@radboudumc.nl  
declined;tayoebong@gmail.com;  
anastasia.gerogantzopoulou@niva.no;  
tommydzus@gmail.com;  
tomasz.kocki@umlub.pl;  
mrykaczewska-czerwinska@sum.edu.pl;  
octavia.sabin@umfcluj.ro;  
borismed@gmail.com;  
svasilev@inep.co.rs;  
silva.dobric@gmail.com;  
gozza@beotel.net;  
sasavukmirovic99@gmail.com;  
dragana.srebro@med.bg.ac.rs;  
mojca.limpel@mf.uni-lj.si;  
tajnistvo@sfd.si;  
andrijana.tivadar@sfd.si;  
natalija.gerbic@sfd.si;  
vanessa.steenkamp@up.ac.za;  
mamza.mothibe@ru.ac.za;  
hafiza.parkar@up.ac.za;  
syk@catholic.ac.kr;  
hgkimm@dankook.ac.kr;  
cm8r@cnu.ac.kr;  
parkjw@snu.ac.kr;  
jouilo@ajou.ac.kr;  
hha@ewha.ac.kr;  
jinthong@chungbuk.ac.kr;  
hjchae@jbnu.ac.kr;  
dhlee@kosin.ac.kr;  
hugo.kupferschmidt@charite.de;  
stephan.kellenberger@unil.ch;  
aywchang@mail.ncku.edu.tw;  
wwlaura1119@ntu.edu.tw;  
noreply19@noreply.com;  
kesaratmu@yahoo.com;  
scuct@mahidol.ac.th;  
yesim.tuncok@gmail.com;  
gunayyetik@gmail.com;  
imvural@yahoo.com;  
anna\_shayakhmetova@yahoo.com;  
rachel@bps.ac.uk;  
clive.page@kcl.ac.uk;  
shaun.lee@bps.ac.uk;  
j.j.coleman@bham.ac.uk;  
trevor.sharp@pharm.ox.ac.uk  
janet.mifsud@um.edu.mt

## Appendix E


Attendees	Country	Society	Member Representation	Membership Vote calculations	Notes
Susana Gorzalczy	Argentina	Argentine Society for Experimental Pharmacology	110	1	
Bridin Murnion	Australia	ASCEPT			
Carl Kirkpatrick	Australia	ASCEPT	250	2	Regional Group
Kevin Pflieger	Australia	ASCEPT			
alastair stewart	Australia	Asia Pacific Federation of Pharmacologists	250	2	Regional Group
Dave Jackson	America	ASPET	4873	10	
Michael Jarvis	America	ASPET			
Vanessa Minervini	America	ASPET			
Xinxin Ding	America	ASPET			
Dagmar Stoiber	Austria	Austrian Pharmacological Society	180	1	
Amrita Ahluwalia	Britain	BPS	3581	10	
Clare Guilding	Britain	BPS			
Rachel Lambert-Forsyth (BPS)	Britain	BPS			
Steve Alexander	Britain	BPS			
Claudio Coddou	Chile	Chilean Society of Pharmacology	179	1	
Guillermo Antonio Diaz Araya	Chile	Chilean Society of Pharmacology			
Patricio Iturriaga	Chile	Chilean Society of Pharmacology			
Darko Modun	Croatia	Croatian Pharmacological Society	154	1	
Dubravka Svob Strac (Croatia)	Croatia	Croatian Pharmacological Society			
Caroline Samer	Switzerland	European Society for Developmental, Perinatal and Pediatric Pharmacology	62	1	
Erika Savontaus	Finland	Finnish Pharmacological Society	506	3	
Pierre Marquet	France	French Pharmacology and Therapeutics Society	400	2	
Ingolf Cascorbi	Germany	German Society for Experimental and Clinical Pharmacology and Toxicology	1988	10	
Beata Sperlagh	Hungary	Hungarian Society for Experimental and Clinical Pharmacology	315	2	
Gordana Dragovic	Serbia	Hungarian Society for Experimental and Clinical Pharmacology			
Bikash Medhit	India	Indian Pharmacological Society	4579	10	
Francesca Levi-Schaffer	Israel	Israel Society for Physiology and Pharmacology	200	1	
Emilio Clementi	Italy	Italian Pharmacological Society	1610	9	
Michael Spedding	France	IUPHAR		*	
Baiba Jansone	Latvia	Latvian Society of Pharmacology	54	1	
Vladimirs Pilipenko	Latvia	Latvian Society of Pharmacology			
Flávio Reis	Portugal	Portuguese Society of Pharmacology	177	1	
Maria José Diógenes	Portugal	Portuguese Society of Pharmacology			
Sasa Vasilev (Serbia)	Serbia	Serbian Pharmacological Society	57	1	
Makhotso Lekhooa	South Africa	South African Society for Basic and Clinical Pharmacology	108	1	
Mamza Mothibe	South Africa	South African Society for Basic and Clinical Pharmacology			
Vanessa Steenkamp	South Africa	South African Society for Basic and Clinical Pharmacology			
Antonio Rodriguez Artalejo	Spain	Spanish Society of Pharmacology	540	3	
Stephan Kellenberger	Switzerland	Swiss Society of Pharmacology and Toxicology	169	1	
Octavia Sabin	Romania	The Romanian Society of Pharmacology	65	1	
A-Gaëlle Bellozzi	France	na			
Olayinka Ogunleye	Nigeria	na			
		Total Society Representation	20407		



1



2


[www.iuphar.org](http://www.iuphar.org)


Established in 1965  
59 Member Societies  
Representing ~37,000 pharmacologists worldwide



3

## IUPHAR Executive Committee from July 2022



**Prof. Ingolf Cascorbi**  
President



**Prof. Francesca Levi-Schaffer**  
President-Elect



**Prof. Michael Spedding**  
Secretary General



**Prof. Pierre Marquet**  
Treasurer



**Prof. Amrita Ahluwalia**  
Basic and Translational  
Pharmacology Section  
Chair



**Prof. Caroline Samer**  
Clinical and Translational  
Pharmacology Section  
Chair



**Prof. Stephen Alexander**  
NC-IUPHAR Committee  
Chair



**Dr. Vanessa Minervini**  
Early Career Researchers  
Section Chair



**Dr. Clare Guilding**  
Education Section Chair



**Prof. Beata Sperlagh**  
Governance Section Chair



**Prof. Emilio Clementi**  
Member-At-Large (2-Year)



**Dr. Olayinka Ogunleye**  
Member-At-Large (4-Year)



**Jesse Howard**  
Director Association Strategy



**Addison Propes**  
Member Service Manager



**Prof. Guan-Hua Du**  
Coopted member



**Prof. Guilherme Suarez-Kurtz**  
Coopted member




**Prof. Bikash Medhi**  
Coopted member



Governance

4



5

# Election Results

## 2024-2026

**President-elect**  
**Secretary General**  
**Chair Basic & Translational Pharmacology Section**  
**Chair Education Section**  
**Chair Governance Section**  
**Member-at-Large**

**Prof. Caroline Samer, Switzerland**  
**Prof. Emilio Clementi, Italy**  
**Prof. Bikash Medhi, India**  
**Prof. Clare Guilding, United Kingdom**  
**Prof. Beáta Sperlagh, Hungary**  
**Prof. Gang Hu, China**

Governance















6




# Confirmation of Election Results

7

## IUPHAR Executive Committee from July 2024

 Prof. Francesca Levi-Schaffer President	 Prof. Caroline Samer President-elect	 Prof. Emilio Clementi Secretary General	 Prof. Pierre Marquet Treasurer	 Prof. Bikah Medhi Chair Basic and Translation Pharmacology Section	 N.N. Chair Clinical and Translational Pharmacology Section
 Prof. Stephen Alexander Chair NC-IUPHAR Committee	 Dr. Vanessa Minervini Chair Early Career Researchers	 Dr. Clare Guiding Chair Education Section	 Prof. Beáta Sperlagh Chair Governance Section	 Prof. Olayinka Ogunleye Member-at-Large	 Prof. Gang Hu Member-at-Large
 Jesse Howard Director Association Strategy	 Kimberly Gibson Administration Officer	<i>Co-opted members to be determined by new EC</i>			

8



9



**Achievements since  
WCP2023 Glasgow**

10



## Achievements since WCP23 Glasgow

1. **Parthenon** an excellent resource, but changes of personnel (Kimberly Gibson has now replaced Addison Propes)
2. **GuidetoMalariaPharmacology.org** completed (via Gates-funded Medicines for Malaria Venture).
3. **THIRTY FIVE** IUPHAR Pubmed references since Glasgow
4. **Regional** meetings in South America (Spanish and Portuguese-speaking countries) Eight presentations in webinars in India,  
Six webinars in natural products with ECRs organized by CNPHARS/IUPHAR,  
Major CNPHARS/IUPHAR NP meeting programmed in July  
SIF/IUPHAR evidence-based NP database now ~360 compounds linked mechanism
5. **IUPHAR meetings secretary appointed** (Beata Sperlagh)
6. **Increased** social media interaction and visibility
7. **IUPHAR News**, please circulate !

11

## Basic & Translational Pharmacology Section

Chair: Amrita Ahluwalia

United Kingdom

Immunopharmacology  
Committee  
Chair: Pasquale Maffia  
United Kingdom/Italy



Natural Products  
Committee  
Chair:  
Valerie Schini-Kerth  
France



Gastrointestinal  
Pharmacology  
Committee  
Chair: Thomas Brzozowski  
Hungary



Neuro/Psycho-  
Pharmacology  
Committee  
Chair: Gary Stephens  
United Kingdom



Cancer Pharmacology  
Committee  
Chair: Jian Ding  
China



Cardiovascular  
Pharmacology  
Committee  
Chair: N.N



Reproducibility &  
Transparency  
Committee  
Chair: Clare Stanford  
United Kingdom



Environmental  
Pharmacology  
Committee  
Chair: Michael Spedding  
France



12



## Achievements since WCP23 Glasgow

### Basic & Translational Section IUPHAR AGM 2024

Chair: Amrita Ahluwalia- Home Society: BPS

- A new Cancer Pharmacology Chair has been appointed Prof Jian Ding of Shanghai Institute of Materia Medica. The Cancer committee is currently being formed and members being invited.
- The Neuropsychopharmacology Committee Chair due to ill-health had to step down and the new leadership of the committee is Prof Gary Stephens (BPS)
- The GI Pharmacology Committee elected a new Chair Thomas Brzozowski (Hungarian Pharmacology Society)
- The IUPHAR Basic & Translational Section have created a new website format that is being.
- The committee established regional representation
- across each committee to be more inclusive.
- 3 webinars
  - (2x NP (ECR focused),
  - 1x Immuno)-
  - further 3 in progress
- 2 articles published across the committees and 1 art
- Committees organised accepted symposia at regional Pharmacology meetings BPS-Dec 2024, ASCEPT 2024
- Immunopharmacology established links with Africa: Africa-Europe Cluster of Research Excellence (CoRE) in Non-Communicable Diseases and Multimorbidity-several meetings and webinars in progress

15 members	
3 ECRs	<a href="https://docs.google.com/spreadsheets">https://docs.google.com/spreadsheets</a>
Representation across each continent	
Asia	Aim to have at least 2-3 countries represented
Africa	Aim to have at least 1-2 countries represented
America	
Europe	Aim to have at least 3-4 countries represented
America	
Australasia	

## Achievements since WCP23 Glasgow

### Clinical & Translational Pharmacology Section

Chair:  
Prof Caroline Samer



- The Clinical and Translational section is made up of **6 committees**, a **Clinical Pharmacology** Committee has been created.
- **World Smart Medication Day**, an annual event in May to promote the visibility of clinical pharmacology world: 3<sup>rd</sup> successful edition in 2024 on Drug Evaluations at the extremes of ages.
- Renewal of **WHO/IUPHAR collaboration** plan (2025-2027) ongoing, continued contribution to WHO 3<sup>rd</sup> Global safety challenge ("Medication without harm") and technical input to WHO documents.
- **Education**: Numerous symposia/courses, including Latin-American countries course, sponsoring EACPT 2024 Rotterdam, co-sponsoring of WHO medication without harm meeting in Colombo (July 2024) by the Sri Lanka Association of Clinical Pharmacology and Therapeutics, etc.
- **Several publications and position papers**
  - BJCP Themed Issue based on WCP symposia from the Geriatric, Global Health & Pharmacogenetics committees
  - Strategies from IUPHAR Geriatric Committee: addressing the gaps in evaluation of new drugs for older adults. Journal of the American Geriatric Society.
- **Partnership** with the Council for International Organizations of Medical Sciences (CIOMS)
- Aim to **increase collaborations** with other sections and subsections, in particular with ECRs.

# Achievements since WCP23 Glasgow Nomenclature & Standards Committee


Chair Stephen Alexander

IUPHAR/BPS Guide to PHARMACOLOGY

An expert-curated resource of pharmacological targets and the substances that act on them

## Publication Impact

NC-IUPHAR and GtoPdb outputs on 2024-04-05



**BJP**  
British Journal  
of Pharmacology

Concise Guide to  
Pharmacology 2023/24

SPH Alexander, E Kelly, A Mathie, JA Peters, EL Weale,  
JF Armstrong, E Faccenda, SD Harding, GP Buhrman,  
JA Colwell, AP Davenport, D Fabbro, M Griebing,  
J Strassburg, JA Davies and CGTP Collaborators

NC-IUPHAR has day-long scientific sessions twice a year (mostly virtually) where speakers are invited to discuss cutting edge developments across pharmacology and updates to the database


**Issue: continuing financing of the database**

IUPHAR

Sections

15

NC-IUPHAR



>500 scientists in  
~105 subcommittees  
arranged primarily by  
molecular targets

Data collected from the subcommittees update the database at [guidetopharmacology.org](http://guidetopharmacology.org) and are published in Pharmacological Reviews & British Journal of Pharmacology

IUPHAR

Sections

16

# Achievements since WCP23 Glasgow

## Education Section

Chair: Clare Guilding



### 8 Publications

### Meetings

**Pharmacokinetics - Tuesday March 12, 2024, 7-9 am EST** Twenty-seven pharmacology educators joined the IUPHAR Core Concepts of Pharmacology Teaching Resources Workshop on the topic of Pharmacokinetics. The session was organized by Jenny Koenig and moderated online by Martin Hawes. In breakout rooms facilitated by Kelly Karpa, Steven Tucker, Janet Mifsud, and Jenny Koenig, participants discussed and developed educational resources that emphasized active learning and re-purposing existing resources to support delivery of learning around 4 pharmacokinetic core concepts.

**Pharmacodynamics - Tuesday 12th March 2024, 1:00 – 4:00 Australian Eastern Daylight Time (GMT +11)** Nineteen pharmacology educators from 7 countries participated in the IUPHAR-Ed Online Meeting Team's Core Concepts of Pharmacology Teaching Resources Workshop on the topic of Pharmacodynamics. This session was organised and moderated online by Anna-Marie Babey. In breakout rooms facilitated by Gavin Dawe, Lynette Fernandes, Willmann Liang, and Carol Restini.

### IUPHAR Education Section Councillors

Quarterly IUPHAR-Ed meetings are extended to:

- PEP Editorial Board
- Core Concepts Research Team
- Education Committee leads from member societies

**Issues:**  
**Move PEP to IUPHAR website,**  
**Organisation of next meeting**  
**(July, Italy)**



**IUPHAR Education Councillors. Row 1 (L to R):** Betty Contarsi (Australia), Lynette Fernandes (Australia), Janet Mifsud (Malta), Kelly Karpa (USA), John Szarek (USA). **Row 2 (L to R):** Jennifer Koenig (England), Paul White (Australia), Nilush Karunaratne (Australia), Arno Wemmers (Grenada), Ely Djouma (Australia). **Row 3 (L to R):** Róise Kelly-Laudacher (Ireland), Octavio Puentes (Colombia), Carolina Restini (USA), Willmann Liang (Hong Kong), Ahmed Wahid (Egypt). **Row 4 (L to R):** Xuechu Zhen (China), Farhan Ahmad Khan (India), Alexandra

Sections

17

# Achievements since WCP23 Glasgow

## New Member Societies

- Armenian Pharmacologist Scientific Public Organization
- Indonesian Pharmacology Society
- The Romanian Society of Pharmacology
- The Sri Lanka Association of Clinical Pharmacology and Therapeutics



Report of Secretary General

18



**Approval of the actions of the  
Executive Committee for the period  
2022 - 2024**

19



**Treasurer's Report**

20

## Treasurer's Report

### Income:

- 2022: \$205,748
- 2023: \$178,139
  - *net difference of -\$27,609 (far less than planned, in part due to the absence of revenue from WCP2023 in Glasgow).*

### Expenses:

- 2023: \$202,487
  - *\$48,000 more than 2022, but ~\$30,000 less than budgeted.*

### Balance 2023:

- Operational balance:  $178,139.28 - 202,486.92 = -\$24,347.64$
- Virtual balance:  $178,139.28 + 45,632.76 - 202,486.92 = +\$21,285.12$

The provisional budget for 2024 plans for \$197,500 of income and \$209,700 of expenses, operating at a tentative (small) net loss.

## Financial report 2023 vs. 2022:

### 1- Income

					Jan - Dec 23	Jan - Dec 22	Change	% Change
Ordinary Income/Expense								
				Income				
				3400 · Annual dues payable to IUPHAR	119 776,31	120 203,81	-427,50	-0,36%
				3401 · Journal Income	30 193,02	25 793,48	4 399,54	17,06%
				3402 · Meetings Income	0,00	12 569,37	-12 569,37	-100,0%
				3405 · Administrative Overhead	0,00	33 743,99	-33 743,99	-100,0%
				3408 · Member & Corporate Donations	57 641,15	10 614,50	47 026,65	443,04%
				3409 · PharmacoCareers.org	631,78	1 973,58	-1 341,80	-67,99%
				3495 · Loss on Accounts Receivable	-31 834,65	-233,80	-31 600,85	-13 516,19%
				6960 · Investment Income	1 731,67	1 083,97	647,70	59,75%
				Total Income	178 139,28	205 748,90	-27 609,62	-13,42%
				Gross Profit	178 139,28	205 748,90	-27 609,62	-13,42%



## Financial report 2023 vs. 2022:

### 2- Expenses

				<b>Travel</b>					
				6640 · Meeting Facilities	10 492,55	2 073,02	8 419,53	406,15%	
				6641 · Transportation	23 737,87	16 339,54	7 398,33	45,28%	
				6642 · Food and Beverage	3 107,21	0,00	3 107,21	100,0%	
				<b>Total Travel</b>	<b>37 337,63</b>	<b>18 412,56</b>	<b>18 925,07</b>	<b>102,78%</b>	
				4400 · Clinical Division Support	6 731,16	1 265,40	5 465,76	431,94%	
				4402 · Secretary-General's Office	7 500,00	7 500,00	0,00	0,0%	
				4403 · Professional Fees	1 820,19	10 610,15	-8 789,96	-82,85%	
				4404 · PEP Curator Support	62 871,41	28 728,35	34 143,06	118,85%	
				4405 · Administrative Support					
				4405.1 · Management Fee	77 832,50	75 000,00	2 832,50	3,78%	
				4405 · Administrative Support - Other	9,06	0,00	9,06	100,0%	
				<b>Total 4405 · Administrative Support</b>	<b>77 841,56</b>	<b>75 000,00</b>	<b>2 841,56</b>	<b>3,79%</b>	

## Financial report 2023 vs. 2022:

### 2- Expenses

				4406 · Young Investigator Awards	180,00	0,00	180,00	100,0%	
				4407 · Guide To Pharmacology	0,00	1 761,76	-1 761,76	-100,0%	
				6520 · Membership Dues paid by IUPHAR	4 689,71	4 836,32	-146,61	-3,03%	
				6560 · Meeting Sponsorship	0,00	2 750,00	-2 750,00	-100,0%	
				6570 · Website	526,22	620,02	-93,80	-15,13%	
				6940 · Bank Fees					
				6942 · Wire Transfer expense	516,11	0,00	516,11	100,0%	
				6940 · Bank Fees - Other	2 444,54	2 450,50	-5,96	-0,24%	
				<b>Total 6940 · Bank Fees</b>	<b>2 960,65</b>	<b>2 450,50</b>	<b>510,15</b>	<b>20,82%</b>	
				6941 · Treasurer's Office	0,00	105,25	-105,25	-100,0%	
				6950 · World Congress	28,39	0,00	28,39	100,0%	
				<b>Total Expense</b>	<b>202 486,92</b>	<b>154 040,31</b>	<b>48 446,61</b>	<b>31,45%</b>	

## 3- 2023 balance

		Jan - Dec 23	Jan - Dec 22	Change	% Change
	<b>Net Ordinary Income</b>	-24 347,64	51 708,59	-76 056,23	-147,09%
	<b>Other Income/Expense</b>				
	<b>Other Income</b>				
	6945 · Gain/Loss Investment Value	46 118,00	-81 798,00	127 916,00	156,38%
	<b>Total Other Income</b>	46 118,00	-81 798,00	127 916,00	156,38%
	<b>Other Expense</b>				
	6949 · Exchange Gain or Loss	485,24	1 514,26	-1 029,02	-67,96%
	<b>Total Other Expense</b>	485,24	1 514,26	-1 029,02	-67,96%
	<b>Net Other Income</b>	45 632,76	-83 312,26	128 945,02	154,77%
	<b>Net Income</b>	<b>21 285,12</b>	<b>-31 603,67</b>	<b>52 888,79</b>	<b>167,35%</b>

Virtual balance = + 178 139.28 + 45 632.76 – 202 486.92 = **+21 285.12 \$**

Actual balance on operational bank accounts = + 178 139.28 + 45 632.76 – 202 486.92 = **-24 347.64 \$**

## IUPHAR Assets (USD)

Category	2018	2019	2020	2021	2022	2023
<b>Investment accounts</b>						
Schweizer Franken Bond	137 994	142 403	157 389	150 059	129 719	152 600
Medium Term Bond Fund - USD	42 807	44 261	44 859	43 971	41 636	43 125
Anlagestrategiefonds - Strategy	94 715	104 262	117 824	118 192	91 111	101 238
UBS Strategy Income Bond	217 548	235 523	244 762	245 765	213 723	225 344
<b>Total investment accounts</b>	<b>493 064</b>	<b>526 449</b>	<b>564 834</b>	<b>557 987</b>	<b>476 189</b>	<b>522 307</b>
Operational - UBS- CHF	1 693	8 253	4 834	3 999	3 714	3 524
Operational - EURO Checking	3 872	16 787	32 547	19 640	38 719	12 864
Operational - USD Checking	137 610	73 603	42 004	59 444	83 131	74 971
<b>Total operational accounts</b>	<b>143 175</b>	<b>98 643</b>	<b>79 385</b>	<b>83 083</b>	<b>125 564</b>	<b>91 359</b>
<b>TOTAL ASSETS</b>	<b>636 239</b>	<b>625 092</b>	<b>644 219</b>	<b>641 070</b>	<b>601 753</b>	<b>613 666</b>



## Approval of the actions of the treasurer for the period 2022 - 2024


27

### Outgoing Officers



**Michael Spedding**

Secretary General  
2012 - 2024



**Ingolf Cascorbi**

President  
2016 - 2024



**Amrita Ahluwella**

Chair Basic & Translational  
Pharmacology Section  
2022 - 2024

28





## **Statement from the outgoing President**

Dr. Ingolf Cascorbi

29



## **Statement from the outgoing Secretary General**

Dr. Michael Spedding

30

## Two new IUPHAR initiatives--

### 1. Environmental pharmacology.

Four hundred million tons of pesticides are applied to the planet, and most of these have modes of action defined by Croplife, the main consortium of producers.

Yet a main measure of activity is toxicological, LD50s, even though we know what concentrations may be in soil or groundwater. Thus we propose that environmental pharmacology, with Kis at site of action and pharmacology at pest, and bystander species will give a better measure of risks to the environment.

Steve Alexander and Michael Spedding

### 2. Industry/biotech contact.

The pharmaceutical industry is the source of most drugs, and has, in the past, supported IUPHAR in classifying receptors and sites for drug action, but this has been less evident over the last two decades. Scientific Liaison: Michael Spedding



## Future Propositions



## Prof. Francesca Levi-Schaffer, PharmD, PhD, FRCPhon

Pharmacology and Experimental Therapeutics  
Isaac and Myrna Kaye Chair of Immunopharmacology  
School of Pharmacy, Institute for Drug Research  
The Hebrew University of Jerusalem  
Jerusalem, Israel



### My Aims for IUPHAR as the new President

- To further scientific research, development and knowledge of pharmacology
- To harmonize pharmacology where the ideas, perceptions and priorities vary due to location, culture, education and gender
- To advance education in pharmacology



President 2024-2026

33

## Strategic Plan

**Vision** To be the leading organization in the world that represents, promotes, and advances pharmacology and its contributions to the global biomedical and healthcare sciences.

**Mission** IUPHAR, in collaboration with pharmacology societies from around the world, will support pharmacology research, education and their application to improve global health.

### Core Values

- **Collaboration:** Facilitating the exchange of information and discussion among investigators and practitioners of pharmacology, focusing on both the acquisition of new knowledge and its applications to clinical care using evidence-based approaches.
- **Innovation:** Promoting the science, development and clinical application of pharmacology.
- **Integrity:** Fostering the ethical conduct and integrity of research, practice, and dissemination of best practices in pharmacology.
- **Generativity:** Developing early career investigators and basic and clinical scientists interested in pharmacology and extending the reach of the field.
- **Inclusivity:** Promoting and welcoming equality, diversity and inclusion within the society and the field.
- **Accessibility:** Ensure accessibility in resource-limited countries.



IUPHAR to 2026

34


## Specific Actions and Activities to Achieve the Aims

- To increase communication and cooperation with other international science organizations (i.e. WHO, ISC, IUIS etc.) and more importantly with national and regional societies
- To open channels of communication where locales, education, culture and gender have different perspectives and priorities in pharmacology. To make pharmacology inclusive on a global level with access open to all, regardless of geographical location
- To support education of pharmacology focusing inb the frame of the Pharmacology Education Project (PEP), and to foster R&D of pharmacology globally and especially in low-income countries
- To establish new IUPHAR committees, i.e. on respiratory, GU, cancer, etc., and to promote new projects in areas such as environmental pharmacology
- To organize future IUPHAR world congresses, general assemblies (every year on a virtual platform), webinars, and meetings.



**Prof. Emilio Clementi,**

Dept. Biomedical and Clinical Sciences, School of Medicine,  
University of Milano, Italy

**What I am currently doing**

*(as member at large and will continue as Secretary General)*

Pharmacological Research is an IUPHAR affiliated journal since 2020 -Taking this as an opportunity to:

- Enhance visibility of affiliated Societies through Special Issues highlighting their history, their main areas of scientific activity, and their future with a section on “the promise”- i.e. articles by young investigators
- Promote interactions and bonding among brilliant IUPHAR young scientists through collaboration at review articles on hot topics (in collaboration with Vanessa and the Early Career Committee)


Worked to implement new strategies for current activities/partnerships/commitments

**How I see IUPHAR- strengths and weaknesses**

- The Union has now a good structure with clearly defined “duties” for the Chairs of the various sections and committees – people start working together on defined projects
- Lean structure with no real headquarters and administration (though Parthenon is doing a good job)
- Interactions with IUPHAR- affiliated national and regional societies
- NC-IUPHAR: a strength and an (economic) weakness


### Future steps


- To interact with affiliated societies on a more direct (one to one meeting) and regular basis to:
  - Listen to their perception of IUPHAR and get suggestions on how to improve IUPHAR strategic actions
  - Plan strategic activities that may improve affiliated societies' standing and visibility
  - Involve as much as possible members from affiliated societies into the IUPHAR activities
- To define priority plans for IUPHAR to develop – e.g. Education programme
- To address the financial issues around NC-IUPHAR
- To help the Meetings-Secretary position to coordinate IUPHAR and affiliated societies webinars
- Increased ECR involvement in IUPHAR (committees - education programme, website)
- Interaction with Industry
- Environmental Pharmacology



# Interested in hosting WCP2030?

**More information  
available on  
IUPHAR.org or**

 **admin@IUPHAR.org**





## Discussion

41

### IUPHAR Membership

#### For discussion:

For small societies from resource-limited countries, the membership-fee should be low cost or free

42

# Thank You

